ClinicalTrials.gg
Not yet recruitingNCT07789379Updated Aug 27, 2026

Adebrelimab Plus Temozolomide ± Hyperbaric Oxygen for Primary Glioblastoma

A Phase 2 interventional study of Adebrelimab and Temozolomide in Glioblastoma, sponsored by Wei Jiang. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Wei Jiang · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a prospective, randomized, open-label, multicenter phase II study. Newly-diagnosed primary glioblastoma patients who have undergone maximal safe resection or biopsy and completed standard concurrent chemoradiotherapy will be enrolled. Subjects will be randomized 1:1 into Arm A (Adebrelimab + Temozolomide + Hyperbaric Oxygen Therapy) or Arm B (Adebrelimab + Temozolomide). The primary endpoint is progression-free survival(PFS). Secondary endpoints include overall survival(OS), objective response rate(ORR), disease control rate(DCR), change of KPS score, safety including TRAE, irAE and SAE. Exploratory objectives include correlation analysis between baseline clinical characteristics / hyperbaric-oxygen-related biomarkers and efficacy-safety outcomes.

02

Conditions studied

  • Glioblastoma

Browse trials for

03

In context

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 94 is above the median of 36 across 1,756 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Wei Jiang is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-70 years, male or female.
  • Newly-diagnosed primary glioblastoma -confirmed; received maximal safe resection or , and completed standard concurrent chemoradiotherapy with temozolomide.
  • Dexamethasone dose ≤4 mg/day at initiation of study treatment.
  • Performance Status(KPS) ≥70.
  • Expected survival ≥3 months.
  • Adequate bone marrow: ≥1.5×10\^9/L; ≥90 g/dL; ≥100×10\^9/L; WBC ≥3.0×10\^9/L.
  • Adequate liver function: /AST/ALP ≤2.5× (≤5×ULN if liver ); total \<1.5×ULN.
  • Adequate coagulation function: PT, , INR ≤1.5×ULN.
  • Female not pregnant / lactating; effective required for fertile females and males during study and 6-month after last study treatment.
  • Signed written , willing to comply with study procedures.
  • Not participating in other interventional clinical trials.

Exclusion criteria

Exclusion Criteria:

  • Prior anti-angiogenic, targeted, immunotherapy (, anti-PD-L1, anti-PD-L2, anti-CD137, CTLA-4 antibody etc.).
  • Progressive disease according to iRANO criteria. Suspicious pseudo-progression should be further evaluated by advanced imaging.
  • Multifocal glioblastoma (separate tumor lesions without overlapping T2/FLAIR signal), or .
  • Prior interstitial brachytherapy, implanted chemotherapy, local injection, convection-enhanced delivery; prior Gliadel wafer placement; prior Optune device usage.
  • Tumor completely located in infratentorial region.
  • Known to temozolomide or adebrelimab components.
  • Dexamethasone >4 mg/day at treatment initiation.
  • History of immunodeficiency, or receiving agents within 7 days before first study drug (except dexamethasone ≤4 mg daily).
  • Uncontrolled concurrent severe disease: active infection, symptomatic congestive heart failure, unstable angina, arrhythmia, uncontrolled hypertension or psychiatric condition interfering with study compliance.
  • Active systemic disease requiring systemic therapy within past 2 years; physiological replacement therapy (thyroxine, insulin etc.) are allowed.
  • Medical conditions unsuitable for hyperbaric oxygen therapy or immunotherapy.
  • Severe anemia or concomitant medications interfering temozolomide absorption.
  • Uncontrolled major psychiatric disorder including depression with CESD-R score ≥16.
  • Cognitive impairment preventing neuro-oncology assessment.
  • Pregnant or lactating women.
  • Participated in other relevant clinical trials within prior 3 months.
  • Life-threatening complication or vegetative state after chemoradiotherapy.
  • Other malignant tumor within past 5 years (except cured carcinoma in-situ, basal-cell skin carcinoma). Poor compliance unable to follow protocol.
  • Substance-use disorder ( criteria: alcohol or drug addiction).
  • Active cardiac disease within 6 months prior to screening: myocardial infarction, unstable angina; \<50%, poorly controlled arrhythmia.
  • Active infection or unexplained fever>38.5℃ at screening / before first dosing (fever attributed to tumor is permitted).
  • Immunodeficiency including active hepatitis; ≥1000 IU/ml; ≥1000 IU/ml. Chronic HBV carrier with HBV-DNA\<2000 IU/ml must receive concurrent antiviral treatment to be eligible.
  • Investigator's judgment that subject is inappropriate for this trial.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Arm A

    Adebrelimab + Temozolomide + Hyperbaric Oxygen Therapy

    Drug: Adebrelimab · Drug: Temozolomide · Procedure: Procedure:Hyperbaric Oxygen Therapy

  • Active comparator
    Arm B

    Adebrelimab + Temozolomide

    Drug: Adebrelimab · Drug: Temozolomide

Interventions

  • 1200 mg intravenous infusion on Day2 of each 28-day cycle, up to 12 months.

  • Oral, Cycle 1:150 mg/m² d2-d6; Cycle 2-12: 200 mg/m² d2-d6, q28d; minimum 6 cycles, maximum12 cycles.

  • ProcedureProcedure:Hyperbaric Oxygen Therapy

    2ATA absolute pressure, 90 minutes once daily, Day1-7 per 28-day cycle. Adebrelimab infusion shall be completed within 24 hours after HBOT.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Time from first study treatment to disease progression (per iRANO criteria) or death from any cause, whichever occurs first. Subjects without progression/death will be censored at last valid tumor assessment.

    Time frame: From first study treatment, tumor imaging performed every 6-9 weeks (±7 days) for the first 24 weeks, then every 12 weeks (±7 days); assessed up to 24-months after first study treatment.

Secondary outcomes

  1. Overall Survival (OS)

    Time from first study treatment to death of any cause. Surviving subjects are censored at date of last survival follow-up.

    Time frame: From first study treatment; survival follow-up every 3 months (±28 days); assessed up to 24-months after first study treatment

  2. Objective Response Rate (ORR)

    Percentage of participants achieving Complete Response (CR) or Partial Response (PR) assessed by iRANO criteria. CR/PR need confirmation ≥4 weeks later.

    Time frame: Baseline; tumor imaging every 6-9 weeks (±7 days) for first 24 weeks, then every 12 weeks (±7 days); assessed up to 24-months after first study treatment.

  3. Disease Control Rate (DCR)

    Percentage of participants achieving CR, PR or Stable Disease (SD) assessed by iRANO criteria.

    Time frame: Baseline, Day1 of each 28-day treatment cycle, End-of-Treatment visit, follow-up visits; assessed up to 24-months after first study treatment.

  4. hange from Baseline in Karnofsky Performance Status (KPS) score

    Incidence, grade, causality and resolution of TRAE, irAE, SAE.

    Time frame: From date of signed informed consent through 90-days after last study drug administration.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

Of 198 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 24 months is below that.

Counting every sponsor, half of 249 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Aug 27, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2029
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07789379
Lead sponsor
Wei Jiang
Responsible party
Wei Jiang (Professor, Chief Physician, Department of Radiation Oncology, Tianjin First Central Hospital) — Sponsor-investigator
First posted
Aug 27, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Aug 27, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion